Evolutionary Clinical Trial for Novel Biomarker-Driven Therapies

Official record

Identifier

NCT07340541

Recruiting locations

country

United States

Interventions studied

SERD* + abemaciclibSERD* + everolimusSERD* + everolimus or capecitabineSOCAntiandrogen

Lead sponsor

UNC Lineberger Comprehensive Cancer Center

Target enrolment

700 participants

Study type

INTERVENTIONAL

Phase

Phase 2

Status

Recruiting

First posted

Jan 14, 2026

Last updated on the registry

Jul 31, 2026

Age

18 Years

Sex

ALL

Study contact

The official record lists a study contact. Contact details are published there and are intentionally not copied to this page.

Eligibility criteria

Reproduced verbatim from the official record. Eligibility is decided by the study team, never by this page.

Inclusion Criteria:

* Written informed consent obtained to participate in the study and HIPAA authorization for release of personal health information.
* Subject is willing and able to comply with study procedures based on the judgement of the investigator.
* Age ≥ 18 years of age at the time of consent
* ECOG Performance Status of 0-2 (see APPENDIX A: ECOG Performance Status Scale).
* Patients must fulfill all eligibility criteria outlined in the LCCC2521 Parent Protocol and consented to LCCC2521 Parent Protocol

Exclusion Criteria:

* Inaccessible metastatic lesion to research biopsy
* Subject has already initiated 2nd line therapy
* Concurrent disease or condition that in the opinion of the treating oncologist renders the patient inappropriate for study participation

Indexed under

Breast Cancer